Atherosclerotic Cardiovascular Disease (ASCVD) is a major cause of death and disability among the elderly, and hyperlipidemia is one of the key risk factors. The elderly population constitutes the main group affected by dyslipidemia. Clinical studies have confirmed that lipid management significantly reduces the morbidity and mortality of ASCVD in the elderly. Therefore, how to strengthen lipid management in the elderly under the premise of multiple comorbidities and polypharmacy has become a hot topic in the field of geriatric medicine. This article systematically reviews the lipid profiles of the elderly, recent research advances in lipid-lowering drugs, and clinical management strategies, aiming to provide guidance for the standardized management of dyslipidemia in older adults.

To explore the effectiveness of applying geriatric comprehensive assessment(CGA) techniques and holistic integrative medicine concepts to the management of geriatric hip fracture.

A total of 84 patients with geriatric hip fracture who visited Changzhou Jintan First People's Hospital from April 1 to December 31, 2024 were selected. They were randomly divided into the observation group and the control group using a random number table, with 42 cases in each group. The observation group was treated with a management model based on comprehensive geriatric assessment techniques and holistic integrative medicine concepts, while the control group received traditional hip fracture diagnosis and treatment. The general information, preoperative waiting time, postoperative rehabilitation start time, length of hospital stay, medical expenses, incidence of complications, as well as Harris hip scores and Barthel Index at 4, 8, and 12 weeks after the operation were compared between the two groups. T test was used to compare measurement data, chi-square test or Fisher's exact probability method was used to compare count data, and repeated measures analysis of variance was used to compare the Harris hip scores and Barthel Index between the two groups at different time points.

The preoperative waiting time, hospital stay, postoperative rehabilitation start time, and hospitalization cost of the patients in the observation group were significantly better than those in the control group, and the differences were statistically significant (t=-2.649, 2.062, -2.352, -2.004; P < 0.05). During the hospitalization period, the incidence rates of pneumonia, constipation and hypoproteinemia in the observation group were significantly lower than those in the control group, and the differences were statistically significant (χ² = 4.141, 4.043, 3.967; P < 0.05); and there were no statistically significant differences in the incidence rates of pressure ulcers, delirium, deep vein thrombosis, incision infection and perioperative mortality between the two groups (P > 0.05). The inter-group and time effects of the Harris score and Barthel index in the two groups of patients after surgery were statistically significant (F=4.256, 5.103, 48.732, 56.847; P < 0.05 or P < 0.01), and the differences between groups at each time point were also statistically significant (P < 0.05).

Applying the CGA technology and the holistic integrated medical concept to the entire process management of elderly hip fractures is conducive to promoting the early postoperative rehabilitation of elderly patients with hip fractures, reducing the occurrence of perioperative complications, and facilitating the recovery of hip joint function and daily living ability after surgery.

With the rapid progression of population aging, issues such as multimorbidity, declining functional reserve, and polypharmacy among older patients have become increasingly prominent. The implant restoration treatment for tooth loss in the elderly is shifting from an evaluation based solely on local anatomical feasibility to comprehensive management that integrates systemic risk assessment and functional maintenance. Based on the core technology of comprehensive geriatric assessment (CGA) and introducing the geriatric "5M" framework (Mind, Mobility, Medications, Multicomplexity, Matters Most), this study systematically reviews the key risk factors and stratified management pathways for the perioperative period of dental implant placement in elderly patients. It primarily focuses on the potential mechanisms underlying the interactions between tooth loss and common geriatric syndromes such as malnutrition, sarcopenia, frailty, and cognitive impairment. It also focuses on how to conduct structured assessment based on the "5M" framework and how to construct a stratified management path centered on CGA, thereby providing clinical references for more benefits for elderly patients undergoing dental implantation.

To investigate the expression profile of Annexin A1 (ANXA1) during the onset and progression of osteoarthritis (OA), and explore its pathogenic mechanism.

Primary human chondrocytes were induced with different concentrations of IL-1β to establish an osteoarthritis-like cell model. Cells were divided into control group (0 ng/mL), mild OA group (5 ng/mL) and severe OA group (10 ng/mL). Immunohistochemistry and immunofluorescence were used to verify the subcellular localization of ANXA1 in chondrocytes. Real-time quantitative polymerase chain reaction and Western blot were applied to detect the expression differences of ANXA1 at mRNA and protein levels, respectively. The changes of collagen typeⅡα1 chain (COL2A1) and matrix metalloproteinase 13 (MMP13) in OA-like chondrocytes were detected to confirm the successful establishment of the OA cell model.Furthermore, ANXA1 silencing group, ANXA1 overexpression group, empty vector control group and simple OA model group were set up in the OA-like cell model. CCK-8 assay and flow cytometry were performed to detect cell proliferation activity and apoptosis of OA-like chondrocytes after ANXA1 silencing or overexpression. Western blot was used to determine the expression of COL2A1 after ANXA1 knockdown. Western blot and co-immunoprecipitation (Co-IP) were utilized to explore the regulatory effect of ANXA1 on the MAPK signaling pathway. Analysis of variance was used to compare the measurement data among multiple groups, while t test was used to compare the measurement data between two groups.

In the OA-like chondrocyte model, the mRNA and protein expression levels of ANXA1 and MMP13 showed an upward trend with the increase of IL-1β concentration, with statistically significant differences (P < 0.05). The CCK-8 results showed that IL-1β inhibited chondrocyte proliferation activity, silencing the ANXA1 gene reversed this inhibitory effect, while overexpression of the ANXA1 gene further reduced chondrocyte proliferation activity. The flow cytometry results showed that compared with the control group, the total apoptosis rates in mild and severe OA groups were elevated from (20.3±1.80)% and (29.7±1.62)% to (32.1±1.96)% and (54.0±1.81)% after ANXA1 overexpression, with statistically significant differences (P < 0.05). In contrast, ANXA1 silencing decreased the total apoptosis rates to (15.4±1.33)% and (23.0±2.14)%. Moreover, ANXA1 overexpression markedly downregulated COL2A1 protein expression relative to the control group (P < 0.05), while ANXA1 knockdown exerted the opposite effect. Western blot and co-immunoprecipitation (Co-IP) assays confirmed that the expression of ANXA1 was positively correlated with the expressions of ERK1/2 and JNK.

The ANXA1 gene inhibits chondrocyte proliferation, and silencing the ANXA1 gene inhibits OA chondrocyte apoptosis. ANXA1 gene may promote chondrocyte apoptosis via the potential MAPK signaling pathway and is an important factor in the occurrence and development of OA.

To evaluate the impact of preoperative chemoradiotherapy on long-term survival in patients aged≥75 years with locally advanced rectal cancer (LARC).

This retrospective cohort study utilized the Surveillance, Epidemiology, and End Results (SEER) database to identify patients aged≥75 years with pathologically confirmed stageⅡ-Ⅲ rectal adenocarcinoma who underwent surgery between January 2010 and December 2020. Patients were stratified into two groups: the neoadjuvant chemoradiotherapy group and the surgery-alone group. Propensity score matching (PSM) balanced baseline characteristics between groups. Primary endpoints included overall survival (OS) and cancer-specific survival (CSS). Kaplan-Meier curves estimated survival rates, with Log-Rank tests comparing between-group differences. COX proportional hazards models identified factors associated with OS and generated hazard ratios (HR) with 95%confidence intervals (CI). The Fine-Gray competing risk model evaluated CSS and calculated subdistribution hazard ratios (sHR)with 95%CI. Sensitivity analyses including multivariable adjustment in the whole-cohort, inverse probability weighting, and overlap weighting were performed.

All of 605 patients enrolled, 419 received preoperative chemoradiotherapy and 186 underwent surgery alone. After 1:1 PSM, 147 matched pairs demonstrated well-balanced baseline characteristics. Median OS was not reached in the preoperative chemoradiotherapy group (95%CI: 49.0 to not reached) versus 43.0 months (95%CI: 35.0-52.0) in the surgery alone group (P < 0.01). Multivariate COX regression identified preoperative chemoradiotherapy as independently associated with reduced all-cause mortality (HR=0.531, 95%CI: 0.363-0.775, P < 0.01). Non-cancer deaths comprised 40.9% of all deaths. Fine-Gray competing risk analysis demonstrated 26.7% reduction in cancer-specific mortality with preoperative chemoradiotherapy (sHR=0.733, 95%CI: 0.451-1.193, P > 0.05), although this did not reach statistical significance. In the whole-cohort multivariable adjustment analysis, neoadjuvant chemoradiotherapy was associated with significantly better OS (HR=0.498, 95%CI: 0.363-0.682, P < 0.01) and CSS (sHR=0.571, 95%CI: 0.378-0.861, P < 0.01) compared with the surgery alone. Inverse probability weighting and overlap weighting analyses yielded consistent results.

Patients aged≥75 years with LARC derive significant OS benefit from preoperative chemoradiotherapy. Advanced age alone should not preclude this treatment approach.

Alzheimer's disease (AD) is a neurodegenerative disease characterized by memory loss and cognitive impairment, which has the highest incidence in the world. Pyroptosis is an inflammatory programmed cell death pattern discovered in recent years. Studies have shown that AD is closely related to pyroptosis. It has been confirmed that amyloid-beta protein and Tau proteins are involved in the occurrence of pyroptosis, and inflammasome and pro-inflammatory cytokines are involved in the pathogenesis of AD in the pathway of pyroptosis activation. Pyroptosis may be the main form of neuronal death. Pyroptosis mediated neuroinflammation plays a central role in the pathogenesis and progression of AD. Inhibition of pyroptosis and downstream inflammatory processes can alleviate the related pathological changes of AD and provide a new clinical therapeutic target.